
DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.
Sponsored and produced by Focus Reports.
about 21 years ago
RX Club Award 2005 Coverageabout 21 years ago
Marketing to Professionals: Detailingabout 21 years ago
Opinion: It's All Relativeabout 21 years ago
Thought Leader: A Q&A with Steve Rauschkolbabout 21 years ago
From the Editor: Lost Worldabout 21 years ago
Washington Report: Out of Commission? Crawford Steps Downabout 21 years ago
Valeant Pharmaceuticals is Soldiering Onabout 21 years ago
Global Report: Drug Evaluation in the UKabout 21 years ago
Legal: State Compulsory Licenses





